FDA Pediatric Study Bill Clears Senate, Will Sunset With Exclusivity Grants
Executive Summary
Legislation restoring FDA's authority to require drug sponsors to conduct trials in children would sunset at the same time as the pediatric exclusivity incentive program under a bill adopted by the Senate July 23
You may also be interested in...
Pediatric Study Requests Would Benefit From Input On Trial Design – Cmte.
FDA hopes that internal process improvements will result in "more clever" requests to companies for pediatric studies under the Best Pharmaceuticals for Children Act
Pediatric Study Requests Would Benefit From Input On Trial Design – Cmte.
FDA hopes that internal process improvements will result in "more clever" requests to companies for pediatric studies under the Best Pharmaceuticals for Children Act
Pediatric Wish List: Longer Exclusivity Reviews, More Public Data
Future legislation should mandate increased public availability of pediatric trial data, Office of Pediatric Therapeutics Director Dianne Murphy said at a June 13 Institute of Medicine drug forum in Washington, D.C